RIG-I activation is critical for responsiveness to checkpoint blockade-Reference-Cited by-同舟云学术

RIG-I activation is critical for responsiveness to checkpoint blockade

Published:2019-09-13 Issue:39 Volume:4 Page:
ISSN:2470-9468
Container-title:Science Immunology
language:en
Short-container-title:Sci. Immunol.

Author:

Heidegger Simon¹²^ORCID,Wintges Alexander¹^ORCID,Stritzke Florian¹²^ORCID,Bek Sarah¹,Steiger Katja³⁴^ORCID,Koenig Paul-Albert⁴⁵⁶^ORCID,Göttert Sascha¹²^ORCID,Engleitner Thomas²⁷,Öllinger Rupert²⁷,Nedelko Tatiana¹²^ORCID,Fischer Julius C.¹⁸^ORCID,Makarov Vladimir⁹^ORCID,Winter Christof⁴⁵^ORCID,Rad Roland²⁴⁷¹⁰^ORCID,van den Brink Marcel R.M.¹¹^ORCID,Ruland Jürgen²⁴⁵^ORCID,Bassermann Florian¹²⁴^ORCID,Chan Timothy A.⁹¹²^ORCID,Haas Tobias¹,Poeck Hendrik¹²^ORCID

Affiliation:

1. Department of Medicine III, School of Medicine, Technical University of Munich, Munich, Germany.

2. Center for Translational Cancer Research (TranslaTUM), School of Medicine, Technical University of Munich, Munich, Germany.

3. Institute of Pathology, School of Medicine, Technical University of Munich, Munich, Germany.

4. German Cancer Consortium (DKTK), Partner-site Munich and German Cancer Research Center (DKFZ), Heidelberg, Germany.

5. Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich, Munich, Germany.

6. Core Facility Nanobodies, University of Bonn, Bonn, Germany.

7. Institute of Molecular Oncology and Functional Genomics, School of Medicine, Technical University of Munich, Munich, Germany.

8. Department of Radiation Oncology, School of Medicine, Technical University of Munich, Munich, Germany.

9. Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, USA.

10. Department of Medicine II, School of Medicine, Technical University of Munich, Munich, Germany.

11. Departments of Immunology and Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.

12. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.

Abstract

Aberrant tumor-intrinsic RIG-I signaling is a crucial mechanism underlying cancer resistance to anti–CTLA-4 immunotherapy.

Funder

Alexander von Humboldt-Stiftung

Melanoma Research Alliance

European Hematology Association

Deutsches Krebsforschungszentrum

European Research Council

Deutsche Forschungsgemeinschaft

Else Kroner-Fresenius-Stiftung

Deutsche Krebshilfe

Dres. Carl Maximilian and Carl Manfred Bayer-Foundation

DKMS Foundation for Giving Life

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine,Immunology

Reference57 articles.

1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

2. Enhancement of Antitumor Immunity by CTLA-4 Blockade

3. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

4. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

5. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MiRNAs and lncRNAs in the regulation of innate immune signaling;Non-coding RNA Research;2023-12

2. Smart and bioinspired systems for overcoming biological barriers and enhancing disease theranostics;Progress in Materials Science;2023-12

3. PTIR1 acts as an isoform of DDX58 and promotes tumor immune resistance through activation of UCHL5;Cell Reports;2023-11

4. The microbial metabolite desaminotyrosine enhances T-cell priming and cancer immunotherapy with immune checkpoint inhibitors;eBioMedicine;2023-11

5. Targeting nucleic acid sensors in tumor cells to reprogram biogenesis and RNA cargo of extracellular vesicles for T cell-mediated cancer immunotherapy;Cell Reports Medicine;2023-09